A photo of Eric Mullins.

Research Director, Hemophilia Treatment Center

Associate Professor, UC Department of Pediatrics

513-517-2234

513-803-5095

Board Certified

My Biography & Research

Biography

As a pediatric hematologist, I specialize in disorders of bleeding and blood clotting. I treat children and adolescents with conditions such as hemophilia, von Willebrand’s disease and disordered menstrual bleeding. I often see patients in the Young Women’s Bleeding Disorder Clinic and the Hemophilia Treatment Center.

I was inspired to pursue my career by my family’s general practitioner, Dr. Cash, who was an exemplary model of how to take care of patients. During medical school at University of Missouri, I was drawn to hematology/oncology because of the science involved in this specialty. I chose pediatrics because I discovered and appreciate that children are much more responsive to following their care plan than adults.

Dr. Bob Janco encouraged my interest in hematology and blood clotting disorders during my residency at Vanderbilt University Medical Center. My fellowship at Cincinnati Children’s Hospital included mentoring by Dr. Ralph Gruppo and Dr. Jay Degen, who pointed me in the direction of my current position.

In addition to treating patients, I perform research. My team and I are examining the impact of blood clotting factors on neurologic disease – diseases of the brain, spinal cord and nerves. We have found that blood clotting plays a key role in the progression of multiple sclerosis, and we hope to find ways to intervene in this disease process.

Clinical Interests

Care of children and adolescents with bleeding and thrombotic disorders; hemophilia; von Willebrand’s disease; Young Women’s Bleeding Disorder Clinic; disordered menstrual bleeding; Hemophilia Treatment Center

Research Interests

Interaction of coagulation factors with immunity and inflammation; inflammatory diseases; multiple sclerosis; sickle cell disease; mouse models of these diseases; coagulation factor knockouts; how hemostatic factors modify the inflammatory response

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Divisions

Cancer and Blood Diseases, Thrombosis, Hemophilia, Hematology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Missouri, Columbia, MO.

Residency: Vanderbilt University Medical Center, Nashville, TN, 2001-2004.

Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2004-2007; Pediatric Hemostasis Fellowship, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008; Chief Fellow, Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.

Board Certifications: Pediatrics, 2004-Present; Pediatric Hematology/Oncology, 2009-Present.

My Publications

Selected Publication

Plasmin-mediated fibrinolysis enables macrophage migration in a murine model of inflammation. Silva, LM; Lum, AG; Tran, C; Shaw, MW; Gao, Z; Flick, MJ; Moutsopoulos, NM; Bugge, TH; Mullins, ES. Blood. 2019; 134:291-303.

Abnormal Uterine Bleeding in Adolescent Women. Mullins, ES; Miller, RJ; Mullins, TL K. Current Pediatrics Reports. 2018; 6:123-131.

Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. Dunn, AL; Ahuja, SP; Mullins, ES. Haemophilia. 2018; 24:e84-e92.

Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. Shaw, MA; Gao, Z; McElhinney, KE; Thornton, S; Flick, MJ; Lane, A; Degen, JL; Ryu, JK; Akassoglou, K; Mullins, ES. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2017; 37:3776-3788.

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Mullins, ES; Stasyshyn, O; Alvarez-Roman, MT; Osman, D; Liesner, R; Engl, W; Sharkhawy, M; Abbuehl, BE. Haemophilia. 2017; 23:238-246.

Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice. Shaw, MA; Kombrinck, KW; McElhinney, KE; Sweet, DR; Flick, MJ; Palumbo, JS; Cheng, M; Esmon, NL; Esmon, CT; Brill, A; et al. Blood. 2016; 128:721-731.

Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Arumugam, PI; Mullins, ES; Shanmukhappa, SK; Monia, BP; Loberg, A; Shaw, MA; Rizvi, T; Wansapura, J; Degen, JL; Malik, P. Blood. 2015; 126:1844-1855.

Evaluation and Management of Adolescents with Abnormal Uterine Bleeding. Mullins, TL K; Miller, RJ; Mullins, ES. Pediatric Annals: a journal of continuing pediatric education. 2015; 44:e218-e222.

Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Mullins, ES; Kombrinck, KW; Talmage, KE; Shaw, MA; Witte, DP; Ullman, JM; Degen, SJ; Sun, W; Flick, MJ; Degen, JL. Blood. 2009; 113:696-704.

Heparin Mimic Material Derived from Cellulose Nanocrystals. Gallagher, ZJ; Fleetwood, S; Kirley, TL; Shaw, MA; Mullins, ES; Ayres, N; Foster, EJ. Biomacromolecules. 2020; 21:1103-1111.